Loading ETF profile…
The First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund (ETF) designed with a clear purpose: to accurately reflect the price movements and income generated by the NYSE Arca Biotechnology Index. Its core objective is to closely match the performance of this benchmark index, before accounting for the fund's operational fees and expenses.
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| CORT | Corcept Therapeutics Inc. | 5.66% | $159.16M |
| VCYT | Veracyte, Inc. | 5.22% | $146.93M |
| NEO | NeoGenomics, Inc. | 5.00% | $140.64M |
| BRKR | Bruker Corporation | 4.28% | $120.56M |
| ALKS | Alkermes Plc | 4.25% | $119.51M |
| ILMN | Illumina, Inc. | 4.04% | $113.66M |
| KRYS | Krystal Biotech, Inc. | 3.94% | $110.81M |
| NTRA | Natera, Inc. | 3.81% | $107.07M |
| AXSM | Axsome Therapeutics, Inc. | 3.65% | $102.75M |
| NBIX | Neurocrine Biosciences, Inc. | 3.56% | $100.10M |
| TECH | Bio-Techne Corporation | 3.44% | $96.89M |
| BIIB | Biogen Inc. | 3.38% | $95.05M |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 3.33% | $93.79M |
| EXEL | Exelixis, Inc. | 3.31% | $93.06M |
| INCY | Incyte Corporation | 3.22% | $90.58M |
| VRTX | Vertex Pharmaceuticals Incorporated | 3.09% | $86.92M |
| ARGX | argenx SE (ADR) | 3.08% | $86.60M |
| RGEN | Repligen Corporation | 3.08% | $86.58M |
| HALO | Halozyme Therapeutics, Inc. | 3.07% | $86.37M |
| BMRN | BioMarin Pharmaceutical Inc. | 2.85% | $80.27M |
| AMGN | Amgen Inc. | 2.77% | $77.96M |
| BNTX | BioNTech SE (ADR) | 2.66% | $74.91M |
| UTHR | United Therapeutics Corporation | 2.57% | $72.34M |
| ONC | BeOne Medicines Ltd. (ADR) | 2.53% | $71.08M |
| GMAB | Genmab A/S (ADR) | 2.48% | $69.91M |